CJC-1295 without DAC vs CJC-1295 with DAC: what is the difference?

Summary at a glance

CJC-1295 is an analog of GHRH that stimulates endogenous GH pulsatility and increases IGF-1. There are two forms: without DAC (Mod GRF(1–29)) – short-acting and closer to physiology, often combined with Ipamorelin; and with DAC – long-acting through albumin binding, providing a sustained increase in IGF-1, but with a higher risk of non-pulsatile stimulation and fluid retention.

What CJC-1295 is — brief

CJC is a hypothalamic peptide that activates somatotrophs in the pituitary and triggers a GH pulse, and increased GH leads to elevated IGF-1 and anabolic effects (protein synthesis, remodelling, bone metabolism).

• Without DAC (Mod GRF(1–29)): the modified 1–29 fragment, resistant to rapid degradation; half-life – short (tens of minutes to ~1–2 h).
• With DAC: contains a Drug Affinity Complex that covalently binds to albumin and extends circulation to days (sustained ↑IGF-1).

This difference – short pulse vs. prolonged exposure – determines the practical usage scenarios.

Why pulsatility matters

Endogenous GH is released in waves (primarily at night, associated with slow-wave sleep). Short, synchronized stimulation is often associated with subjectively better sleep and recovery with moderate ↑IGF-1, whereas prolonged exposure can lead to more pronounced but harder-to-control metabolic effects. See a review on GH pulsatility (PubMed).

Pharmacokinetics and dosing paradigms (research framework)

• Without DAC: short action → 1–3 times daily, often in the evening; rationale – enhancing nocturnal GH pulsations. Synergy with Ipamorelin (GHS-R agonist).
• With DAC: long action → 1–2 times weekly; stable ↑IGF-1, but less control over timing and a higher chance of water retention/headache.

Benefits: where they overlap and where they differ

Common potential benefits (category „Peptides for recovery and anabolic“)

• Improved slow-wave sleep and subjective recovery.
• Collagen remodelling and support of connective tissues (GH → IGF-1).
• Improvements in body composition with controlled diet and training.
• Support for muscle protein synthesis when combined with adequate protein intake.

Specifics of CJC-1295 without DAC

Pros More physiological pulsatility, fine dose control, good evening timing, often less water retention; excellent synergy with Ipamorelin.

Cons More frequent administration and dependence on sleep/diet hygiene.

Specifics of CJC-1295 with DAC

Pros Convenience (infrequent dosing), sustained ↑IGF-1 (days), potentially stronger anabolic background.

Cons Higher risk of non-pulsatile stimulation and fluid retention/headache; harder timing control; caution with glucose regulation.

What the scientific publications show (briefly)

• For CJC-1295 with DAC in humans, prolonged ↑IGF-1 has been reported for 1–2 weeks after a dose, with local reactions and transient fluid retention (PubMed).
• For Mod GRF(1–29) / CJC-1295 without DAC: short GH peaks, a more controllable profile; synergy with selective GHS-R agonists like Ipamorelin – low impact on ACTH/cortisol.
• Reviews on GH pulsatility emphasize the importance of the natural rhythm for sleep and recovery (review).
• For metabolic focus on visceral adipose tissue: tesamorelin has RCT data.

Which variant is used for what (research logic)

• Sleep and recovery: without DAC, evening timing, often combined with Ipamorelin.
• More sustained anabolic background / IGF-1: with DAC, but with stricter monitoring for edema/headache/glucose.
• Body composition with a metabolic focus: Tesamorelin ± Ipamorelin; CJC with DAC can provide an IGF-1 background but is not the only option.
• Redox protection under high training load: Glutathione as background for oxidative stress.

Combinations

When not to use / cautions

• Active or undiagnosed neoplasms.
• Uncontrolled hyperglycaemia/insulin resistance, severe edema/cardiopathy.
• Pregnancy/breastfeeding; minors.
• Anti-doping: GH secretagogues are on the WADA Prohibited List – athletes should avoid them.
• Allergies/hypersensitivity to excipients/solvents.

Practical notes (logistics and safety)

• Lyophilised vs. pre-mixed solution: in the absence of stability data for ready-to-use liquids, the dry form is the more conservative choice. See the detailed article.
• Timing: without DAC – often evening; with DAC – weekly regimen, less „fine-tuning“ to sleep.
• Monitoring: subjective markers (sleep, edema, headache), IGF-1, glucose/lipids in vulnerable individuals, blood pressure.
• Diet/protein: GH signalling without adequate protein/energy → limited results.

Which is the „best“ variant?

There is no universal winner – it depends on the goal and the risk profile. For fine, physiologically supported recovery/sleep → without DAC (+ Ipamorelin). When a sustained IGF-1 background is desired and closer monitoring is acceptable → with DAC. For a metabolic focus (visceral fat) consider Tesamorelin. Under high training stress add Glutathione for redox balance.

View the „Peptides for recovery and anabolic“ category Ask a question

Sources

1. Teichman SL et al. – „CJC-1295, a long-acting GHRH analog“: prolonged increase in IGF-1 and safety in humans.
2. Raun K. et al. – „Ipamorelin, the first selective GH secretagogue“: selectivity and low impact on ACTH/cortisol.
3. Veldhuis JD, Bowers CY – review on GH pulsatility and the physiology of GHRH/ghrelin.
4. Falutz J. et al. – Tesamorelin and visceral adipose tissue in randomized clinical trials.
5. Review of glutathione and muscle recovery (redox biology, PMC).
6. WADA – Prohibited List (GH & secretagogues).
7. Peptology – Lyophilised vs. pre-mixed peptides: stability and logistics.